 
 
Medical and Drug
Policies
Policies & Guidelines
Advanced Imaging
Draft Policies
Autism Spectrum Mandate
Behavioral Health
Blue Advantage Policies
Advanced Imaging
Draft Policies
Genetic Testing
Draft Genetic Testing Policies
Medical Policies
Draft Policies
Final Policies
Provider-Administered Drug Policies (Excluding Oncology)
Current Provider-Administered Drug Policies
Draft Provider-Administered Drug Policies
Previous Provider-Administered Drug Policies
Provider-Administered Oncology Drug Policies
Current Provider-Administered Oncology Drug Policies
Draft Provider-Administered Oncology Drug Policies
Previous Provider-Administered Oncology Drug Policies
Radiation Therapy
Draft Policies
Chronic Condition Management
Genetic Testing
Draft Genetic Testing Policies
HealthSmartRx Smart RxAssist Program
Hemophilia Drugs
Draft Hemophilia Drug Policies
Final Hemophilia Drug Policies
Hemophilia Drug Prior Authorization
PEEHIP Hemophilia Drug Program
Medical Policies
Draft Medical Policies
Final Medical Policies
Provider-Administered Drug Policies (Excluding Oncology)
Draft Provider-Administered Drug Policies
Final Provider-Administered Drug Precertification Policies
Mandatory Site of Service
Provider-Administered Drug Claim Edit Policies
Voluntary Site of Service
Provider-Administered Oncology Drug Policies
Current Provider-Administered Oncology Drug Policies
Draft Provider-Administered Oncology Drug Policies
Radiation Therapy
Draft Policies
Self-Administered Drug Policies
Draft Self-Administered Drug Policies
Final Self-Administered Drug Policies
Self-Administered Drug Prior Authorization Forms
Transgender Services
 
vp-0008
 
Print
 
 
BackAloxi® (palonosetron) (Intravenous)
Policy Number: VP-0008
Last Review Date: 03/31/2023
Date of Origin:
 10/17/2008
Dates Reviewed: 
06/2009, 12/2009, 09/2010, 12/2010, 02/2011, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012,
12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016,
05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 04/2019, 04/2020, 04/2021, 04/2022, 04/2023
FOR PEEHIP Members Only -Coverage excludes the provider-administered medication(s) outlined in this drug policy from
being accessed through a specialty pharmacy. It must be obtained through buy and bill.
I. Length of Authorization
Coverage will be provided for 6 months and may be renewed, unless otherwise specified.
PONV: Coverage will be provided for 1 dose and may not be renewed.
II. Dosing Limits
A
. 
Quantity Limit (max daily dose) [NDC unit]:
Aloxi 0.25 mg/5 mL solution for injection: 1 vial per 7 day supply
Aloxi 0.075 mg/1.5 mL solution for injection: 1 vial
B
. 
Max Units (per dose and over time) [HCPCS Unit]:
CINV:
10 billable units per 7 days
PONV:
3 billable units x 1 dose only
III. Initial Approval Criteria
Coverage is provided in the following conditions:
For PEEHIP Members Only
If patient is receiving moderately emetogenic chemotherapy (MEC) the patient must have tried and had an inadequate
response, intolerance or contraindication to another 5HT3-antagonist (i.e., ondansetron or granisetron) while receiving
the current chemotherapy regimen; 
AND
Prevention of Chemotherapy induced Nausea and vomiting (CINV) in Adults † 
Patient is receiving highly emetogenic chemotherapy (HEC)
*
; 
OR
Patient is receiving moderately emetogenic chemotherapy (MEC); 
AND
Palonosetron is NOT covered for:
Breakthrough emesis; 
OR
Repeat dosing in multi-day emetogenic chemotherapy regimens
Prevention of Chemotherapy induced Nausea and vomiting (CINV) in Pediatric Patients 
†
 
Patient is at least 1 month old and less than 17 years old; 
AND
Patient is receiving emetogenic chemotherapy; 
AND
 Palonosetron is NOT covered for:
Breakthrough emesis; 
OR
 
Repeat dosing in multi-day emetogenic chemotherapy regimens
Prevention of post-operative nausea and vomiting (PONV) in Adults † 
*Highly emetogenic chemotherapy (HEC)
:
Highly Emetogenic Chemotherapy (HEC)
1-4,6
1-4,6
1Carboplatin
Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Doxorubicin
Epirubicin
Fam-trastuzumab deruxtecan-nxki
Ifosfamide
Mechlorethamine
Melphalan ≥140 mg/m
Sacituzumab govitecan-hziy
Streptozocin
The following can be considered HEC in certain patients
Dactinomycin
Daunorubicin
Idarubicin
Irinotecan
Methotrexate ≥250mg/m
Oxaliplatin
Trabectedin
The following regimens can be considered HEC
FOLFOX
FOLFIRI
FOLFIRINOX; FOLFOXIRI
AC (any anthracycline +
cyclophosphamide)
**
 
Failure is defined as:
Two or more documented episodes of vomiting attributed to the current chemotherapy regimen
† 
FDA Approved Indication(s); 
‡
 Compendium Recommended Indication(s); 
Ф
 Orphan Drug
IV. Renewal Criteria
 
Coverage may be renewed based upon the following criteria:
Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including
prerequisite therapy), performance status, etc. identified in section III; 
AND
Disease response; 
AND
Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: serotonin syndrome, severe
QT prolongation, severe hypersensitivity reactions (including anaphylaxis and anaphylactic shock), etc.
V. Dosage/Administration
 
Indication
Dose
Preve
n
tion of chemotherapy-induced nausea and vomiting
in adults
Administer 0.25 mg intravenously, no more frequently than weekly, prior to emetogenic
chemotherapy
Prevention of chemotherapy-induced nausea and vomiting
in pediatrics
Administer 20 mcg/kg (max of 1.5 mg) intravenously, no more frequently than weekly,
prior to emetogenic chemotherapy
Post-operative nausea and vomiting
Administer 0.075 mg intravenously immediately before the induction of anesthesia
VI. Billing Code/Availability Information
HCPCS Code:
J2469 – Injection, palonosetron HCl, 25 mcg: 1 billable unit = 25 mcg (0.025 mg)
NDC:
Aloxi 0.25 mg/5 mL solution for injection; single-dose vial: 69639-103-xx
*
Aloxi 0.075 mg/1.5 mL solution for injection; single-dose vial: 69639-103-xx (not commercially available)
*
Generics available from multiple manufacturers
VII. References
1
. 
Aloxi [package insert]. Switzerland; Helsinn Healthcare SA; April 2020. Accessed March 2023.
2
. 
Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium
) palonosetron.
National Comprehensive Cancer Network, 2023. The NCCN Compendium
 is a derivative work of the NCCN Guidelines
.
NATIONAL COMPREHENSIVE CANCER NETWORK
, NCCN
, and NCCN GUIDELINES
 are trademarks owned by the
National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go
online to NCCN.org. Accessed March 2023.
3
. 
Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium
) Antiemesis. Version
1.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium
 is a derivative work of the NCCN
2
2
1-3
1
®
®
®
®
®
®
®
®
®
®
®Guidelines
. NATIONAL COMPREHENSIVE CANCER NETWORK
, NCCN
, and NCCN GUIDELINES® are trademarks
owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the
Compendium, go online to NCCN.org. Accessed March 2023.
4
. 
Roila F, Molassiotis A, Herrstedt J, et al. MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy
and Radiotherapy-Induced Nausea and Vomiting: ESMO Clinical Practice Guidelines. Ann Oncol (2016) 27 (suppl 5): v119-
v133.
5
. 
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline
Update. J Clin Oncol. 2017 Oct 1;35(28):3240-3261.
6
. 
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology 2020 38:24, 2782-
2797.
Appendix 1 – Covered Diagnosis Codes
ICD-10
ICD-10 Description
R11.0
Nausea
R11.10
Vomiting, unspecified
R11.11
Vomiting without nausea
R11.12
Projectile vomiting
R11.2
Nausea with vomiting, unspecified
T41.0X5A
Adverse effect of inhaled anesthetics, initial encounter
T41.1X5A
Adverse effect of intravenous anesthetics, initial encounter
T41.205A
Adverse effect of unspecified general anesthetics, initial encounter
T41.295A
Adverse effect of other general anesthetics, initial encounter
T41.45XA
Adverse effect of unspecified anesthetic, initial encounter
T45.1X5A
Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5D
Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T45.1X5S
Adverse effect of antineoplastic and immunosuppressive drugs, sequela
T45.95XA
Adverse effect of unspecified primarily systemic and hematological agent , initial encounter
T45.95XD
Adverse effect of unspecified primarily systemic and hematological agent, subsequent encounter
T45.95XS
Adverse effect of unspecified primarily systemic and hematological agent, sequela
T50.905A
Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
T50.905D
Adverse effect of unspecified drugs, medicaments and biological substances, subsequent encounter
T50.905S
Adverse effect of unspecified drugs, medicaments and biological substances, sequela
T88.59XA
Other complications of anesthesia, initial encounter
Z51.11
Encounter for antineoplastic chemotherapy
Z51.12
Encounter for antineoplastic immunotherapy
Appendix 2 – Centers for Medicare and Medicaid Services (CMS)
Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50
Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs) and Local
Coverage Article (LCAs) may exist and compliance with these policies is required where applicable. 
They can be found at:
http://www.cms.gov/medicare-coverage-database/search.aspx
. 
Additional indications may be covered at the discretion of the
health plan.
Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA)
: N/A
Medicare Part B Administrative Contractor (MAC) Jurisdictions
Jurisdiction
Applicable State/US Territory
Contractor
E (1)
CA,HI, NV, AS, GU, CNMI
Noridian Healthcare Solutions, LLC
F (2 & 3)
AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ
Noridian Healthcare Solutions, LLC
5
KS, NE, IA, MO
Wisconsin Physicians Service Insurance Corp (WPS)
6
MN, WI, IL
National Government Services, Inc. (NGS)
H (4 & 7)
LA, AR, MS, TX, OK, CO, NM
Novitas Solutions, Inc.
8
MI, IN
Wisconsin Physicians Service Insurance Corp (WPS)
®
®
®CPT codes, descriptions and data copyright ©BCBSPREVIOUSYEAR American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT codes, descriptions and data copyright ©BCBSPREVIOUSYEAR American Dental Association. All rights reserved.
© BCBSCURRENTYEAR Blue Cross and Blue Shield of Alabama is an independent licensee of the Blue Cross and Blue Shield Association. 
N (9)
FL, PR, VI
First Coast Service Options, Inc.
J (10)
TN, GA, AL
Palmetto GBA, LLC
M (11)
NC, SC, WV, VA (excluding below)
Palmetto GBA, LLC
L (12)
DE, MD, PA, NJ, DC 
(includes Arlington & Fairfax counties and
the city of Alexandria in VA)
Novitas Solutions, Inc.
K (13 & 14)
NY, CT, MA, RI, VT, ME, NH
National Government Services, Inc. (NGS)
15
KY, OH
CGS Administrators, LLC
Medicare Part B Administrative Contractor (MAC) Jurisdictions
Jurisdiction
Applicable State/US Territory
Contractor
 
 